Across TCGA pan-cancer cohorts, ACSL6 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of ACSL6’s most consistent transcriptional readouts.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ACSL6 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ACSL6 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.
CCRCC are the cancer types where ACSL6 tumor–normal differential expression is most reproducible.